SLXN
Silexion Therapeutics Corp2.6100
+0.0500+1.95%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
8.16MP/E (TTM)
0.01Basic EPS (TTM)
349.09Dividend Yield
0%Recent Filings
10-K
8-K
8-K
8-K
SIL204 Phase 2/3 submission
Silexion Therapeutics submitted its Phase 2/3 clinical trial application in Israel for SIL204 in locally advanced pancreatic cancer on December 16, 2025. Backed by toxicology studies showing no systemic toxicity and preclinical data with up to 99.7% KRAS mutation inhibition, trials target Q2 2026 start at Sheba Medical Center. Germany/EU filings follow in Q1 2026. Execution hits stride.
8-K
BfArM greenlights SIL204 trial design
Silexion Therapeutics secured positive feedback from Germany's BfArM on its Phase 2/3 trial design for SIL204 in locally advanced pancreatic cancer. The advice covers clinical design, dosing, patient strategy, and manufacturing, bolstering submissions to Israel's Ministry of Health by Q4 2025 end and Germany in Q1 2026. Trial initiation stays on track for H1 2026. Regulatory hurdles persist.
BLRX
BioLineRx Ltd.
3.01-0.17
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
LADX
LadRx Corporation
0.11+0.00
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
SION
Sionna Therapeutics, Inc.
42.89+0.13
SLN
Silence Therapeutics Plc - Amer
6.27-0.33
SLRX
Salarius Pharmaceuticals, Inc.
0.72-0.06
SNSE
Sensei Biotherapeutics, Inc.
8.08+0.19
TNGX
Tango Therapeutics, Inc.
8.96-0.16
XLO
Xilio Therapeutics, Inc.
0.65+0.00